Somewhere between starting a GLP-1 medicine and reaching your target, someone will tell you that you are losing muscle, not fat. It is the most common worry attached to these drugs and one of the most poorly explained. The 2026 evidence is clearer than the discourse: most of what comes off is fat, lean mass does fall as well, the frailty claims are not supported by data, and what you do about it matters most at the point you stop. Here is the practical version.
Body composition studies of weight loss, by any method, show that lean mass falls alongside fat. Depending on the study, lean tissue accounts for somewhere around a fifth to two fifths of total weight lost. That is not unique to GLP-1 drugs. It happens with dieting and with bariatric surgery too.
What made it a headline is the sheer scale of loss these drugs produce. A larger total loss means a larger absolute lean-mass loss, even when the proportion is unremarkable.
Three things, and they need holding together rather than picking between.
Most of the loss is fat. The evidence consistently shows fat as the majority of what comes off. The picture of people wasting away is not what the data describes.
Lean mass does fall. Trials and real-world data agree on this. It is measurable and it is real.
The frailty claim is not supported. Reviews argue there is no good evidence that GLP-1 weight loss causes frailty or sarcopenia as clinical conditions, a position aired at the 2026 American Diabetes Association meeting. Falling lean mass is not the same as becoming frail.
There is a further nuance usually missed. "Lean mass" is not all muscle. It includes water, glycogen and the connective and structural tissue that supports a larger body. Some of that decrease is an appropriate adjustment to carrying less weight. A person 25 kilograms lighter does not need the same supporting structure they needed before.
Here is the part that changes behaviour, and the reason to care even if you feel fine.
Weight regain after stopping is common. What comes back is disproportionately fat. If you lost a significant amount of muscle on the way down and then regain weight after stopping, you can end up at a similar weight with a worse body composition than you started with, and a lower resting metabolic rate, which makes the next attempt harder.
That is the real argument for protecting muscle. Not vanity, and not strength for its own sake, but keeping the ground you gained.
The commonly cited target is at least 1.0 to 1.2 grams of protein per kilogram of ideal body weight per day. Note "ideal", not current. For many people that lands somewhere between 70 and 100 grams a day.
The difficulty is mechanical. These drugs work by making you less hungry and keeping food in your stomach longer, so hitting a protein target on a much smaller appetite takes planning:
If nausea is bad enough that you are eating very little for days at a time, that is worth raising with your prescriber rather than pushing through, because a dose adjustment may be the answer.
Protein supplies the material; a stimulus tells the body to keep it. Without one, some of that material is lost regardless of intake.
It does not require a gym membership or an elaborate programme. Two or three sessions a week covering the major muscle groups, with resistance that genuinely challenges you in the last few repetitions, is the shape of it. Bodyweight, bands and household objects all count. Progressing over time matters more than what you lift.
Walking is excellent for many things and is not a substitute here. Cardiovascular exercise does not provide the same signal to preserve muscle.
Home scales that claim to measure body fat use bioimpedance, and their readings shift with hydration, time of day and recent meals. A single reading tells you almost nothing. A consistent trend, measured at the same time under the same conditions, tells you a little more.
More reliable everyday signals:
If you want something objective, a DEXA scan measures body composition properly. It is not routinely offered for this, but it is available privately in many places and a baseline is more useful than a single scan later.
Muscle mass declines with age anyway, from around the fourth decade, and the consequences of losing more of it are not cosmetic. In later life, muscle is what keeps people out of hospital after a fall and independent in their own homes.
That does not mean older adults should avoid these medicines. Obesity carries its own serious risks, and the benefits can be substantial. It does mean the protein target and the resistance training move from advisable to essential, and it is a fair thing to raise directly: given my age, how are we protecting my muscle while I lose this weight?
The scale will not tell you the difference between fat and muscle, which is why it is a poor guide on its own. More useful signals: whether everyday strength is holding, meaning stairs, shopping, getting up from a low chair, and whether your clothes change shape as well as size.
Reasonable questions for your clinician: should I have my body composition assessed, is my protein intake sufficient for my size and dose, and what is the plan for maintaining this if and when I stop. That last question is the one most worth asking early, and it is covered in our guide to GLP-1 drugs and what they do to your body. If you want to think it through before an appointment, the health chat will answer specific questions with sources.
Lean mass does fall on GLP-1 medicines, but most of the weight lost is fat, and the evidence does not support the claim that these drugs cause frailty. The risk that actually bites is regaining fat after stopping with less muscle than you started with. Protein at 1.0 to 1.2 grams per kilogram of ideal body weight, protein first at each meal, and two or three resistance sessions a week is the whole protocol. It is unglamorous and it works.
This article is for general education and is not a substitute for professional medical advice. Discuss nutrition and exercise plans with your doctor, particularly if you take medicines that affect appetite or blood sugar.
The first randomised trial of a multi-cancer blood test missed its primary endpoint but cut stage IV diagnoses. What that means, what it costs, and who it is genuinely for.
COVID is rising across most US states this September. The presentation has shifted: a severe sore throat and stomach upset now dominate, and loss of taste and smell has become uncommon.
Last winter's severe flu season was driven by the H3N2 subclade K variant. All three strains in this season's vaccine have been updated. What that means for when you get your shot.